 |
|
Single-Agent Therapy for Hodgkin's Disease
Stephen K. Carter, MD;
Robert B. Livingston, MD
Arch Intern Med. 1973;131(3):377-387.
Abstract
We have reviewed existing data on single drugs in the chemotherapy of Hodgkin's disease in order to place in perspective the recent results with regimens employing combinations of drugs. Combination chemotherapy, by historical comparison with single-drug therapy, is clearly superior in the induction of complete remission of disease. However, many single agents, particularly those in the antimetabolite and antibiotic classes of antitumor drugs, have been evaluated only minimally and may yet play important roles in the design of future combination therapies.
Author Affiliations
Bethesda, Md
From the National Cancer Institute, Bethesda, Md.
Footnotes
Received for publication Sept 13, 1972; accepted Oct 2, 1972.
Read before the Symposium on Hodgkin's Disease, St. Louis, Oct 8, 1971, sponsored by the National Cancer Institute, Cancer Clinical Investigation Review Committee, Clinical Investigations Branch.
Reprint request to National Cancer Institute, Bethesda, Md 20014 (Dr. Carter).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Procarbazine-Free OEPA-COPDAC Chemotherapy in Boys and Standard OPPA-COPP in Girls Have Comparable Effectiveness in Pediatric Hodgkin's Lymphoma: The GPOH-HD-2002 Study
Mauz-Korholz et al.
JCO 2010;28:3680-3686.
ABSTRACT
| FULL TEXT
Salvage Therapy in Hodgkin's Lymphoma
Byrne and Gockerman
The Oncologist 2007;12:156-167.
ABSTRACT
| FULL TEXT
A New Combination Chemotherapy for Resistant Hodgkin Disease
Vinciguerra et al.
JAMA 1977;237:33-35.
ABSTRACT
|
